983 resultados para Aritmie cardiache, Elettrostimolazione cardiaca, Pacemaker, Rate-responsive pacing, Defibrillatori
Resumo:
Il cuore è uno dei principali organi vitali dell’organismo umano e la sua fisiologica attività è indispensabile per sostenere uno stile di vita conforme alle esigenze del singolo individuo. Le aritmie cardiache, alterazioni del ritmo, possono compromettere o limitare la vita di un paziente che ne è affetto. Specifiche aritmie cardiache vengono trattate con l’impianto di dispositivi cardiaci impiantabili, i defibrillatori, che generano una stimolazione elettrica nel tessuto cardiaco allo scopo di ripristinare un ritmo cardiaco fisiologico. Il presente elaborato descrive come tali dispositivi siano in grado di correggere le aritmie cardiache, garantendo la sicurezza del paziente e permettendogli di svolgere le normali attività quotidiane . Il primo capitolo andrà ad analizzare il cuore dal punto di vista anatomico e fisiologico per capirne il funzionamento non affetto da patologie. Il secondo capitolo concentrerà l’analisi sui defibrillatori impiantabili per stimolazione cardiaca (ICD), facendo luce sulla storia, sulle funzioni primarie,sui componenti interni,sulle patologie legate all’utilizzo,sulle tipologie presenti in commercio e sul metodo d’impianto. Il terzo capitolo è incentrato sul monitoraggio remoto degli ICD (home-monitoring), attraverso il quale il paziente può trasmettere per via transtelefonica al centro cardiologico di riferimento i dati tecnici e clinici desumibili dall’interrogazione del dispositivo impiantato, senza necessità di ricorrere al controllo ambulatoriale tradizionale. L’home-monitoring nei pazienti portatori di dispositivo impiantabile si è dimostrato efficace per l’individuazione di malfunzionamenti e di instabilità cliniche in misura sovrapponibile rispetto al controllo ambulatoriale tradizionale, offrendo però significativi vantaggi in termini di qualità della vita e di gestione delle risorse sanitarie. Infine saranno presentate le conclusioni di tale elaborato.
Resumo:
Il primo obiettivo di questo lavoro di tesi è quello di sviluppare il primo modello matematico di potenziale d'azione pacemaker umano: è vero che gli studi elettrofisiologici pubblicati sull'uomo non hanno ancora raggiunto la mole di risultati ottenuti, invece, sugli altri mammiferi da laboratorio, ma i tempi possono ritenersi "maturi", in quanto i dati disponibili in letteratura sono sufficienti e adeguati allo scopo. Il secondo obiettivo di questo lavoro di tesi nasce direttamente dall'esigenza clinica di definire le relazioni causa-effetto tra la mutazione T78M della proteina caveolina-3 e le varie forme di aritmie cardiache riscontrate, ad essa associate. Lo scopo è quello di stabilire quale sia il link tra genotipo della mutazione e fenotipo risultante, ovvero colmare il gap esistente tra i dati sperimentali in vitro in possesso ed i meccanismi di alterazione delle correnti ioniche affette, per arrivare a osservare l'effetto che ne deriva sull'attività elettrica delle cellule. Proprio in relazione a quest'ultimo punto, i due obiettivi del lavoro convergono: l'analisi degli effetti indotti dalla mutazione T78M è, infatti, effettuata sul modello di potenziale d'azione di nodo senoatriale umano sviluppato (oltre che su altri modelli atriali).
Resumo:
Heart rate variability (HRV) exhibits fluctuations characterized by a power law behavior of its power spectrum. The interpretation of this nonlinear HRV behavior, resulting from interactions between extracardiac regulatory mechanisms, could be clinically useful. However, the involvement of intrinsic variations of pacemaker rate in HRV has scarcely been investigated. We examined beating variability in spontaneously active incubating cultures of neonatal rat ventricular myocytes using microelectrode arrays. In networks of mathematical model pacemaker cells, we evaluated the variability induced by the stochastic gating of transmembrane currents and of calcium release channels and by the dynamic turnover of ion channels. In the cultures, spontaneous activity originated from a mobile focus. Both the beat-to-beat movement of the focus and beat rate variability exhibited a power law behavior. In the model networks, stochastic fluctuations in transmembrane currents and stochastic gating of calcium release channels did not reproduce the spatiotemporal patterns observed in vitro. In contrast, long-term correlations produced by the turnover of ion channels induced variability patterns with a power law behavior similar to those observed experimentally. Therefore, phenomena leading to long-term correlated variations in pacemaker cellular function may, in conjunction with extracardiac regulatory mechanisms, contribute to the nonlinear characteristics of HRV.
Resumo:
At the highest level of competitive sport, nearly all performances of athletes (both training and competitive) are chronicled using video. Video is then often viewed by expert coaches/analysts who then manually label important performance indicators to gauge performance. Stroke-rate and pacing are important performance measures in swimming, and these are previously digitised manually by a human. This is problematic as annotating large volumes of video can be costly, and time-consuming. Further, since it is difficult to accurately estimate the position of the swimmer at each frame, measures such as stroke rate are generally aggregated over an entire swimming lap. Vision-based techniques which can automatically, objectively and reliably track the swimmer and their location can potentially solve these issues and allow for large-scale analysis of a swimmer across many videos. However, the aquatic environment is challenging due to fluctuations in scene from splashes, reflections and because swimmers are frequently submerged at different points in a race. In this paper, we temporally segment races into distinct and sequential states, and propose a multimodal approach which employs individual detectors tuned to each race state. Our approach allows the swimmer to be located and tracked smoothly in each frame despite a diverse range of constraints. We test our approach on a video dataset compiled at the 2012 Australian Short Course Swimming Championships.
Resumo:
Introducción: El sincope vasovagal es la principal causa de pérdida transitoria de la consciencia. Las guías internacionales de tratamiento del síncope recomiendan con un nivel de evidencia débil, el implante de marcapasos para pacientes refractarios al tratamiento médico que tienen respuesta cardioinhibitoria. Hasta el momento no existe una revisión sistemática que resuma la mejor evidencia disponible a la fecha sobre la estimulación con marcapasos en síncope vasovagal para disminuir recurrencias. Métodos: Revisión sistemática de la literatura de ensayos clínicos aleatorizados acerca del uso del marcapasos en síncope vasovagal para disminuir recurrencias. Resultados: La búsqueda inicial arrojó un total de 299 resultados, de los cuales solo 8 cumplieron los criterios de selección. Se evaluó la recurrencia de síncopes en el grupo de estimulación con marcapasos comparada con el grupo sin estimulación. Con diferencias metodológicas marcadas en los estudios seleccionados en general no hay una evidencia sólida para asegurar que el marcapasos disminuye recurrencias de síncope vasovagal. Discusión: El marcapasos en síncope vasovagal no tiene efecto benéfico en disminución de recurrencias cuando se implanta a toda la población refractaria al tratamiento médico para disminuir recurrencias. Solamente un grupo con características clínicas muy seleccionadas podría beneficiarse de la estimulación con marcapasos para disminuir recurrencias de síncope. Conclusión: La evidencia disponible sugiere que el marcapasos no tiene efecto en disminución de recurrencias en todo el grupo de pacientes con síncope vasovagal refractarios a tratamiento médico.
Resumo:
BACKGROUND New generation transcatheter heart valves (THV) may improve clinical outcomes of transcatheter aortic valve implantation. METHODS AND RESULTS In a nationwide, prospective, multicenter cohort study (Swiss Transcatheter Aortic Valve Implantation Registry, NCT01368250), outcomes of consecutive transfemoral transcatheter aortic valve implantation patients treated with the Sapien 3 THV (S3) versus the Sapien XT THV (XT) were investigated. An overall of 153 consecutive S3 patients were compared with 445 consecutive XT patients. Postprocedural mean transprosthetic gradient (6.5±3.0 versus 7.8±6.3 mm Hg, P=0.17) did not differ between S3 and XT patients, respectively. The rate of more than mild paravalvular regurgitation (1.3% versus 5.3%, P=0.04) and of vascular (5.3% versus 16.9%, P<0.01) complications were significantly lower in S3 patients. A higher rate of new permanent pacemaker implantations was observed in patients receiving the S3 valve (17.0% versus 11.0%, P=0.01). There were no significant differences for disabling stroke (S3 1.3% versus XT 3.1%, P=0.29) and all-cause mortality (S3 3.3% versus XT 4.5%, P=0.27). CONCLUSIONS The use of the new generation S3 balloon-expandable THV reduced the risk of more than mild paravalvular regurgitation and vascular complications but was associated with an increased permanent pacemaker rate compared with the XT. Transcatheter aortic valve implantation using the newest generation balloon-expandable THV is associated with a low risk of stroke and favorable clinical outcomes. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT01368250.
Resumo:
La posible asociación entre el desarrollo de fibrilación auricular (FA) con la presencia de cardiopatía chagásica en una población portadora de dispositivos cardiacos de estimulación no está descrita. Se presenta un estudio de tipo cohorte retrospectivo realizado en la FCI que recopila las principales características clínicas de una población de pacientes con cardiopatía de variada etiología y portadores de dispositivos cardiacos buscando evaluar la incidencia de FA en presencia de cardiomiopatía de origen chagásico y no chagásico. A la fecha no se cuenta con una base de datos institucional ni regional que contenga las variables analizadas. Durante los 5 meses que duró la construcción de la base de datos se incluyeron 99 sujetos de investigación. Se implantaron 42 marcapasos bicamerales, 39 cardiodesfibriladores bicamerales, 6 dispositivos correspondientes cardiodesfibrilador con función de resincronización cardiaca, 2 resincronizadores cardiacos sin función de cardiodesfibrilador y 7 cardiodesfibriladores unicamerales. De los 99 sujetos recolectados se presentaron 8 desenlaces (FA de novo) y de esos solamente 1 pertenece al grupo de pacientes con cardiomiopatía chagásica. Este número reducido de desenlaces no permitió desarrollar un modelo de regresión de Cox y ni otros tipos de análisis estadísticos planteados en el protocolo inicial debido al bajo número de casos y pobre poder estadístico. Esta dificultad es inherente a la naturaleza del problema a estudiar y al corto tiempo de seguimiento. Por lo anterior no se puede establecer si existe una relación entre la presencia de serología positiva para infección por T. Cruzi y la presencia de FA de novo.
Resumo:
Heart diseases are the leading cause of death worldwide, both for men and women. However, the ionic mechanisms underlying many cardiac arrhythmias and genetic disorders are not completely understood, thus leading to a limited efficacy of the current available therapies and leaving many open questions for cardiac electrophysiologists. On the other hand, experimental data availability is still a great issue in this field: most of the experiments are performed in vitro and/or using animal models (e.g. rabbit, dog and mouse), even when the final aim is to better understand the electrical behaviour of in vivo human heart either in physiological or pathological conditions. Computational modelling constitutes a primary tool in cardiac electrophysiology: in silico simulations, based on the available experimental data, may help to understand the electrical properties of the heart and the ionic mechanisms underlying a specific phenomenon. Once validated, mathematical models can be used for making predictions and testing hypotheses, thus suggesting potential therapeutic targets. This PhD thesis aims to apply computational cardiac modelling of human single cell action potential (AP) to three clinical scenarios, in order to gain new insights into the ionic mechanisms involved in the electrophysiological changes observed in vitro and/or in vivo. The first context is blood electrolyte variations, which may occur in patients due to different pathologies and/or therapies. In particular, we focused on extracellular Ca2+ and its effect on the AP duration (APD). The second context is haemodialysis (HD) therapy: in addition to blood electrolyte variations, patients undergo a lot of other different changes during HD, e.g. heart rate, cell volume, pH, and sympatho-vagal balance. The third context is human hypertrophic cardiomyopathy (HCM), a genetic disorder characterised by an increased arrhythmic risk, and still lacking a specific pharmacological treatment.
Resumo:
The aim of this study was to evaluate whether a change of left ventricular ejection fraction (LVEF) depending on percentage of right ventricular pacing is found in a real-life setting of a pacemaker clinic.
Resumo:
Background: Today’s medical devices are powered by batteries with a limited energy storage capacity. Depleted batteries have to be replaced, exposing the patients to the risk of adverse events. Thus, a method for harvesting energy inside the body is desirable since it would allow building devices without batteries. Methods: A miniaturized intravascular Tesla turbine was implanted as an arteriovenous shunt between the common carotid artery and external jugular vein of a pig. The harvested energy was used to power a custom-built temporary cardiac pacemaker. Results: At a flow rate of ~150 ml/min, an output power of 0.4 mW was measured. Successful ventricular pacing was performed. Conclusion: Harvesting energy from the circulation using an intravascular turbine is technically feasible and provides enough energy to power a cardiac pacemaker.
Resumo:
AIMS Today's cardiac pacemakers are powered by batteries with limited energy capacity. As the battery's lifetime ends, the pacemaker needs to be replaced. This surgical re-intervention is costly and bears the risk of complications. Thus, a pacemaker without primary batteries is desirable. The goal of this study was to test whether transcutaneous solar light could power a pacemaker. METHODS AND RESULTS We used a three-step approach to investigate the feasibility of sunlight-powered cardiac pacing. First, the harvestable power was estimated. Theoretically, a subcutaneously implanted 1 cm(2) solar module may harvest ∼2500 µW from sunlight (3 mm implantation depth). Secondly, ex vivo measurements were performed with solar cells placed under pig skin flaps exposed to a solar simulator and real sunlight. Ex vivo measurements under real sunlight resulted in a median output power of 4941 µW/cm(2) [interquartile range (IQR) 3767-5598 µW/cm(2), median skin flap thickness 3.0 mm (IQR 2.7-3.3 mm)]. The output power strongly depended on implantation depth (ρSpearman = -0.86, P < 0.001). Finally, a batteryless single-chamber pacemaker powered by a 3.24 cm(2) solar module was implanted in vivo in a pig to measure output power and to pace. In vivo measurements showed a median output power of >3500 µW/cm(2) (skin flap thickness 2.8-3.84 mm). Successful batteryless VVI pacing using a subcutaneously implanted solar module was performed. CONCLUSION Based on our results, we estimate that a few minutes of direct sunlight (irradiating an implanted solar module) allow powering a pacemaker for 24 h using a suitable energy storage. Thus, powering a pacemaker by sunlight is feasible and may be an alternative energy supply for tomorrow's pacemakers.
Resumo:
BACKGROUND: Contemporary pacemakers (PMs) are powered by primary batteries with a limited energy-storing capacity. PM replacements because of battery depletion are common and unpleasant and bear the risk of complications. Batteryless PMs that harvest energy inside the body may overcome these limitations. OBJECTIVE: The goal of this study was to develop a batteryless PM powered by a solar module that converts transcutaneous light into electrical energy. METHODS: Ex vivo measurements were performed with solar modules placed under pig skin flaps exposed to different irradiation scenarios (direct sunlight, shade outdoors, and indoors). Subsequently, 2 sunlight-powered PMs featuring a 4.6-cm2 solar module were implanted in vivo in a pig. One prototype, equipped with an energy buffer, was run in darkness for several weeks to simulate a worst-case scenario. RESULTS: Ex vivo, median output power of the solar module was 1963 μW/cm2 (interquartile range [IQR] 1940-2107 μW/cm2) under direct sunlight exposure outdoors, 206 μW/cm2 (IQR 194-233 μW/cm2) in shade outdoors, and 4 μW/cm2 (IQR 3.6-4.3 μW/cm2) indoors (current PMs use approximately 10-20 μW). Median skin flap thickness was 4.8 mm. In vivo, prolonged SOO pacing was performed even with short irradiation periods. Our PM was able to pace continuously at a rate of 125 bpm (3.7 V at 0.6 ms) for 1½ months in darkness. CONCLUSION: Tomorrow's PMs might be batteryless and powered by sunlight. Because of the good skin penetrance of infrared light, a significant amount of energy can be harvested by a subcutaneous solar module even indoors. The use of an energy buffer allows periods of darkness to be overcome.